Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 50, Issue -, Pages 106S-121SPublisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.108.057281
Keywords
PET; therapy monitoring; hypoxia; steroid receptors; proliferation
Funding
- National Cancer Institute [R25-CA96945]
Ask authors/readers for more resources
This review article discusses PET agents, other than F-18-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non-F-18-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the therapeutic response. Four sections related to the nature of the tracers are included: radiotracers of DNA synthesis, such as the 2 most promising agents, the thymidine analogs 3'-F-18-fluoro-3'-deoxythymidine and F-18-1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine; agents for PET imaging of hypoxia within tumors, such as Cu-60/62/64-labeled diacetyl-bis(N-4-methylthiosemicarbazone) and F-18-fluoromisonidazole; amino acids for PET imaging, including the most popular such agent, L-[methyl-C-11]methionine; and agents for the imaging of tumor expression of androgen and estrogen receptors, such as 16 beta-F-18-fluoro-5 alpha-dihydrotestosterone and 16 alpha-F-18-fluoro-17 beta-estradiol, respectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available